Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

Dallas, Texas United States of America
Improvements in heart health were observed regardless of the amount of weight lost by semaglutide users.
Semaglutide had fewer serious adverse events than placebo but more people left the study due to gastrointestinal symptoms.
Semaglutide reduces major adverse cardiovascular events (MACEs) by 20% compared to placebo for individuals with overweight or obesity and cardiovascular disease.
Semaglutide's ability to reduce cardiovascular events held up even for those with normal A1c levels at baseline.
Semaglutide users sustained weight loss of an average of 10% during a four-year period.
Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

In recent developments, semaglutide, a popular weight-loss drug marketed as Wegovy or Ozempic, has shown promising results in reducing major adverse cardiovascular events (MACEs) and improving heart health for individuals with overweight or obesity and cardiovascular disease. The findings come from the SELECT trial, which included researchers from UT Southwestern Medical Center.

According to the study published in Diabetes Care and The New England Journal of Medicine, semaglutide significantly reduced MACEs by 20% compared to placebo for non-diabetics with preexisting cardiovascular disease. This reduction was observed regardless of blood sugar levels.

The SELECT trial also revealed that people taking semaglutide sustained weight loss for up to four years, dropping an average of 10% of their body weight during that period. Moreover, Wegovy users showed improvements in heart health irrespective of the amount of weight lost.

At two years, 12% of people on semaglutide reached normal weight status and more than 55% no longer qualified as having obesity BMI class. By 208 weeks, participants had reduced waist circumference by an average of about three inches and kept the weight off.

Weight loss was significant regardless of a person's sex, race, body size, location, age, and preexisting health conditions. Semaglutide users also had fewer serious adverse events than those taking a placebo but more people left the study due to gastrointestinal symptoms such as nausea and diarrhea.

In 2023, results from the SELECT trial showed that participants had a 20% lower risk of major adverse cardiovascular events such as heart attack and stroke. A separate analysis presented at the European Congress on Obesity in May showed that people had lower odds of developing heart issues regardless of the amount of weight they lost, suggesting alternative mechanisms for improved cardiovascular outcomes beyond reduction in adiposity.

Semaglutide's ability to reduce cardiovascular events held up even for those who had normal A1c levels at baseline. The reduction in MACEs was similar across all subgroups of A1c change and independent of baseline A1c.

These findings underscore the importance of addressing both weight loss and heart health in individuals with overweight or obesity and cardiovascular disease. Semaglutide's potential to improve both aspects makes it a valuable tool for healthcare professionals.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

No Doubts Found At Time Of Publication

Sources

88%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

SELECT: Semaglutide Reduces CV Events and Diabetes Risk

Medscape Alicia Ault Monday, 24 June 2024 11:33
  • Unique Points
    • The SELECT trial found that semaglutide reduced cardiovascular events and the risk of progression to diabetes by 73% in people with established cardiovascular disease and obesity compared to placebo.
    • , Semaglutide improved glycemic control in people at high risk of cardiovascular disease, but did not slow glycemic progression over time.
    • Among those with a normal A1c level at baseline, 0.5% of semaglutide recipients developed diabetes compared to 1.3% of placebo recipients.
    • Semaglutide’s ability to reduce cardiovascular events held up even for those who had normal A1c levels at baseline.
    • The reduction in cardiovascular events was similar across all subgroups of A1c change and independent of baseline A1c.
  • Accuracy
    • Semaglutide improved glycemic control in people at high risk of cardiovascular disease, but did not slow glycemic progression over time.
    • Semaglutide has been found to significantly reduce people’s chances of heart attack and stroke.
  • Deception (50%)
    The article discusses the benefits of semaglutide for cardiovascular events and diabetes risk reduction in people with established cardiovascular disease and obesity. While it provides information about the study and its findings, it does not disclose that the study was sponsored by Novo Nordisk, the company that markets semaglutide. This omission could be seen as an attempt to hide potential conflicts of interest.
    • The original SELECT trial evaluated the effect of semaglutide on patients with overweight or obesity and atherosclerotic cardiovascular disease on major adverse cardiovascular events (MACE). As previously reported by Medscape Medical News, the anti-obesity drug reduced MACE by around 20% vs placebo in this high-risk population.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

88%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Now weight-loss drug can ease symptoms of deadly heart failure, as findings of new trial offers hope...

Daily Mail Kate Pickles Sunday, 23 June 2024 21:00
  • Unique Points
    • Semaglutide helps ease symptoms of preserved ejection fraction (HFpEF) in both men and women.
    • Semaglutide significantly reduces people's chances of heart attack and stroke.
    • Semaglutide has been found to significantly reduce people’s chances of heart attack and stroke.
    • Dr. Sonya Babu-Narayan has spoken of the potential transformational impact on someone’s life due to the kind of improvements seen with semaglutide.
  • Accuracy
    • Women lost more weight (9.6%) than men (7.2%)
    • HFpEF affects around half a million people in the UK with an annual mortality rate of 10-15% and typical hospitalization once a year.
    • Dr. Sonya Babu-Narayan has spoken of the potential transformational impact on someone's life due to the kind of improvements seen with semaglutide.
  • Deception (50%)
    The article is deceptive in its omission of mentioning that semaglutide, marketed as Ozempic or Wegovy, is a prescription medication that has not been peer-reviewed for the treatment of heart failure. The author presents the drug's effectiveness without linking to any peer-reviewed studies. Additionally, the article implies that semaglutide can cure heart failure by reducing inflammation and improving exercise capacity, which may lead readers to believe it is a proven solution when in fact it is still under investigation.
    • Patients were also able to do more exercise and had reduced levels of inflammation.
    • The analysis is the first to look at the effects of the jab on men and women separately in relation to preserved ejection fraction (HFpEF), where the heart pumps normally but is too stiff to fill properly.
    • Semaglutide, marketed as Ozempic and Wegovy, helped women lose more weight than men but provided the same benefits to members of each sex who suffer from a common type of heart failure.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Semaglutide lowers cardiovascular risk regardless of blood sugar

UT Southwestern Medical Center Monday, 24 June 2024 11:36
  • Unique Points
    • A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level.
    • Semaglutide was originally approved by the FDA at a dose of 1.0 mg for adults with Type 2 diabetes and later for chronic weight management at a dose of 2.4 mg.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

How Long Can You Sustain Weight Loss on Wegovy? New Research Might Have the Answer

Health Magazine Monday, 24 June 2024 11:38
  • Unique Points
    • The SELECT trial, which included 17,604 non-diabetics with preexisting cardiovascular disease as well as overweight or obesity, revealed new insights into Wegovy’s effectiveness.
    • People taking the drug Wegovy sustained weight loss for up to four years and dropped an average of 10% of their body weight during that period.
    • Wegovy users also showed improvements in heart health irrespective of the amount of weight lost.
    • At two years, 12% of people on semaglutide reached normal weight status and more than 55% no longer qualified as having obesity BMI class.
    • By 208 weeks, participants had reduced waist circumference by an average of about three inches, dropped an average of 10% of their body weight, and kept the weight off.
    • Weight loss was significant regardless of a person’s sex, race, body size, location, age, and preexisting health conditions.
    • People taking the drug had fewer serious adverse events than those taking a placebo but more people left the study due to gastrointestinal symptoms such as nausea and diarrhea.
    • In 2023, results from the SELECT trial showed that participants had a 20% lower risk of major adverse cardiovascular events such as heart attack and stroke.
    • A separate analysis presented at the European Congress on Obesity in May showed that people had lower odds of developing heart issues regardless of the amount of weight they lost, suggesting alternative mechanisms for improved cardiovascular outcomes beyond reduction in adiposity.
  • Accuracy
    • Semaglutide has been found to significantly reduce people’s chances of heart attack and stroke.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication